Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Study of EG-COVID mRNA SARS-CoV-2 Vaccine in Healthy Adults
KCT0006670Phase 2Completed
- Sponsor
- EyeGene, Inc.
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of EG-COVID in coronavirus disease 2019 (COVID-19), sponsored by EyeGene, Inc.. Started Sep 2021; status: completed.
02
Drugs
EG-COVID
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on KCT0006670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006670.